C4 Therapeutics Files 8-K

Ticker: CCCC · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1662579

C4 Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyC4 Therapeutics, Inc. (CCCC)
Form Type8-K
Filed DateDec 9, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

C4 Therapeutics filed a routine 8-K, no major news.

AI Summary

C4 Therapeutics, Inc. filed an 8-K on December 9, 2024, reporting other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates C4 Therapeutics is fulfilling its reporting obligations with the SEC, but it does not disclose any new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain any new material information or significant events.

Key Players & Entities

  • C4 Therapeutics, Inc. (company) — Registrant
  • 0001628280-24-050349 (filing_id) — Accession Number
  • December 9, 2024 (date) — Filing Date
  • 490 Arsenal Way, Suite 120 (address) — Principal Executive Offices
  • Watertown, MA 02472 (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing for C4 Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 9, 2024.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted to the SEC on December 9, 2024.

What is the exact name of the company filing this report?

The exact name of the company is C4 Therapeutics, Inc.

Where are C4 Therapeutics, Inc.'s principal executive offices located?

C4 Therapeutics, Inc.'s principal executive offices are located at 490 Arsenal Way, Suite 120, Watertown, MA 02472.

Does this filing disclose any specific new material events or financial results?

Based on the provided text, this filing appears to be a routine report and does not explicitly disclose any specific new material events or financial results beyond the standard reporting categories.

Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-12-09 09:49:23

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo

Filing Documents

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 Slides from C4 Therapeutics, Inc.'s ASH Annual Meeting Presentation, dated December 8, 2024 99.2 Press release issued December 8, 2024 99.3 Corporate presentation of the Company dated December 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: December 9, 2024 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.